Arizona State Retirement System Purchases 365 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Arizona State Retirement System raised its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSPFree Report) by 1.7% during the 3rd quarter, Holdings Channel.com reports. The firm owned 21,351 shares of the company’s stock after purchasing an additional 365 shares during the period. Arizona State Retirement System’s holdings in CRISPR Therapeutics were worth $969,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the company. Signaturefd LLC lifted its holdings in shares of CRISPR Therapeutics by 12.5% in the third quarter. Signaturefd LLC now owns 2,124 shares of the company’s stock worth $96,000 after buying an additional 236 shares in the last quarter. Vontobel Holding Ltd. lifted its holdings in shares of CRISPR Therapeutics by 1.3% in the second quarter. Vontobel Holding Ltd. now owns 18,900 shares of the company’s stock worth $1,061,000 after buying an additional 249 shares in the last quarter. CWM LLC lifted its holdings in shares of CRISPR Therapeutics by 80.7% in the third quarter. CWM LLC now owns 582 shares of the company’s stock worth $26,000 after buying an additional 260 shares in the last quarter. Voya Investment Management LLC lifted its holdings in shares of CRISPR Therapeutics by 1.2% in the fourth quarter. Voya Investment Management LLC now owns 22,129 shares of the company’s stock worth $900,000 after buying an additional 269 shares in the last quarter. Finally, Cetera Advisor Networks LLC lifted its holdings in shares of CRISPR Therapeutics by 4.2% in the fourth quarter. Cetera Advisor Networks LLC now owns 7,538 shares of the company’s stock worth $306,000 after buying an additional 306 shares in the last quarter. Hedge funds and other institutional investors own 68.20% of the company’s stock.

CRISPR Therapeutics Price Performance

CRSP stock opened at $66.88 on Wednesday. The company has a market capitalization of $5.31 billion, a PE ratio of -14.96 and a beta of 1.73. CRISPR Therapeutics AG has a 12 month low of $37.55 and a 12 month high of $76.97. The firm’s 50-day moving average is $64.14 and its 200 day moving average is $55.09.

Insider Buying and Selling

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 50,000 shares of the stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $60.51, for a total transaction of $3,025,500.00. Following the transaction, the chief executive officer now directly owns 187,377 shares in the company, valued at approximately $11,338,182.27. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.10% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities analysts have recently commented on CRSP shares. Royal Bank of Canada boosted their target price on shares of CRISPR Therapeutics from $50.00 to $57.00 and gave the stock a “sector perform” rating in a report on Monday, December 11th. Needham & Company LLC boosted their price target on shares of CRISPR Therapeutics from $85.00 to $88.00 and gave the stock a “buy” rating in a research report on Monday, December 11th. Morgan Stanley reduced their price target on shares of CRISPR Therapeutics from $43.00 to $42.00 and set an “underweight” rating on the stock in a research report on Monday, November 13th. TD Cowen cut shares of CRISPR Therapeutics from a “market perform” rating to an “underperform” rating and set a $30.00 price target on the stock. in a research report on Monday, December 11th. Finally, Mizuho restated a “buy” rating and issued a $82.00 price target on shares of CRISPR Therapeutics in a research report on Friday, December 8th. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat.com, CRISPR Therapeutics currently has an average rating of “Hold” and a consensus price target of $68.39.

Get Our Latest Stock Report on CRISPR Therapeutics

CRISPR Therapeutics Company Profile

(Free Report)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

See Also

Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CRISPR Therapeutics AG (NASDAQ:CRSPFree Report).

Institutional Ownership by Quarter for CRISPR Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.